Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.

Article  PubMed  PubMed Central  Google Scholar 

Chen Z, Chen J, Gao Y, Quan M. Heterogeneous clinical and pathological landscapes of HER2 positive colorectal cancer. Expert Rev Anticancer Ther. 2021;21(10):1097–104. https://doi.org/10.1080/14737140.2021.1944108.

CAS  Article  PubMed  Google Scholar 

Benson AB, Venook AP, Al-Hawary MM, et al. Colon Cancer, Version 2.2021, NCCN Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(3):329–59. https://doi.org/10.6004/jnccn.2021.0012.

Article  PubMed  Google Scholar 

André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350(23):2343–51. https://doi.org/10.1056/NEJMoa032709.

Guo Y, Xiong BH, Zhang T, Cheng Y, Ma L. XELOX vs. FOLFOX in metastatic colorectal cancer: an updated meta-analysis. Cancer Invest. 2016;34(2):94–104. https://doi.org/10.3109/07357907.2015.1104689.

CAS  Article  PubMed  Google Scholar 

Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16(13):1306–15. https://doi.org/10.1016/S1470-2045(15)00122-9.

CAS  Article  PubMed  Google Scholar 

Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol. 2007;25(30):4779–86. https://doi.org/10.1200/JCO.2007.11.3357.

CAS  Article  PubMed  Google Scholar 

Kazazi-Hyseni F, Beijnen JH, Schellens JH. Bevacizumab. Oncologist. 2010;15(8):819–25. https://doi.org/10.1634/theoncologist.2009-0317.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Venook AP, Niedzwiecki D, Lenz HJ, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA. 2017;317(23):2392–401. https://doi.org/10.1001/jama.2017.7105.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065–75. https://doi.org/10.1016/S1470-2045(14)70330-4.

CAS  Article  PubMed  Google Scholar 

Seufferlein T, Ettrich TJ, Stein A, et al. Predicting resistance to first-line FOLFOX plus bevacizumab in metastatic colorectal cancer: final results of the multicenter, international PERMAD trial. J Clin Oncol. 2021;39(3_suppl):115–115. https://doi.org/10.1200/JCO.2021.39.3_suppl.115.

Article  Google Scholar 

Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–12. https://doi.org/10.1016/S0140-6736(12)61900-X.

CAS  Article  PubMed  Google Scholar 

Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16(6):619–29. https://doi.org/10.1016/S1470-2045(15)70156-7.

CAS  Article  Google Scholar 

Van Cutsem E, Mayer RJ, Laurent S, et al. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. Eur J Cancer. 2018;90:63–72. https://doi.org/10.1016/j.ejca.2017.10.009.

CAS  Article  PubMed  Google Scholar 

Pfeiffer P, Yilmaz M, Moller S, et al. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21(3):412–20. https://doi.org/10.1016/S1470-2045(19)30827-7.

CAS  Article  PubMed  Google Scholar 

Behjati S, Tarpey PS. What is next generation sequencing? Arch Dis Child Educ Pract Ed. 2013;98(6):236–8. https://doi.org/10.1136/archdischild-2013-304340.

Article  PubMed  PubMed Central  Google Scholar 

Bewicke-Copley F, Arjun Kumar E, Palladino G, Korfi K, Wang J. Applications and analysis of targeted genomic sequencing in cancer studies. Comput Struct Biotechnol J. 2019;17:1348–59. https://doi.org/10.1016/j.csbj.2019.10.004.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Wei Q, Zhang Y, Gao J, et al. Clinicopathologic characteristics of HER2-positive metastatic colorectal cancer and detection of HER2 in plasma circulating tumor DNA. Clin Colorectal Cancer. 2019;18(3):175–82. https://doi.org/10.1016/j.clcc.2019.05.001.

CAS  Article  PubMed  Google Scholar 

Chung C. Predictive and prognostic biomarkers with therapeutic targets in colorectal cancer: a 2021 update on current development, evidence, and recommendation. J Oncol Pharm Pract. 2021:10781552211005525. https://doi.org/10.1177/10781552211005525.

Fanelli GN, Dal Pozzo CA, Depetris I, et al. The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer. Cancer Cell Int. 2020;20:30. https://doi.org/10.1186/s12935-020-1117-2.

Article  PubMed  PubMed Central  Google Scholar 

Golshani G, Zhang Y. Advances in immunotherapy for colorectal cancer: a review. Therap Adv Gastroenterol. 2020;13:1756284820917527. https://doi.org/10.1177/1756284820917527.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Shiu K-K, Andre T, Kim TW, et al. KEYNOTE-177: phase III randomized study of pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer. J Clin Oncol. 2021;39(3_suppl):6–6. https://doi.org/10.1200/JCO.2021.39.3_suppl.6.

Article  Google Scholar 

Guarini C, Grassi T, Pezzicoli G, Porta C. Beyond RAS and BRAF: HER2, a new actionable oncotarget in advanced colorectal cancer. Int J Mol Sci. 2021;22(13):6813. https://doi.org/10.3390/ijms22136813.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Bitar L, Zouein J, Haddad FG, Eid R, Kourie HR. HER2 in metastatic colorectal cancer: a new to target to remember. Biomark Med. 2021;15(2):133–6. https://doi.org/10.2217/bmm-2020-0491.

CAS  Article  PubMed  Google Scholar 

Meric-Bernstam F, Hurwitz H, Raghav KPS, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019;20(4):518–30. https://doi.org/10.1016/S1470-2045(18)30904-5.

CAS  Article  PubMed  PubMed Central  Google Scholar 

• Ross JS, Fakih M, Ali SM, et al. Targeting HER2 in colorectal cancer: the landscape of amplification and short variant mutations in ERBB2 and ERBB3. Cancer. 2018;124(7):1358–73. https://doi.org/10.1002/cncr.31125. Lays out the differences between HER2 amplification and HER2 mutations and demonstrates the incidence of their association with other common alterations such as TP53, KRAS, and MSI.

CAS  Article  PubMed  Google Scholar 

Connell CM, Doherty GJ. Activating HER2 mutations as emerging targets in multiple solid cancers. ESMO Open. 2017;2(5):e000279. https://doi.org/10.1136/esmoopen-2017-000279.

Article  PubMed  PubMed Central  Google Scholar 

Yagisawa M, Sawada K, Nakamura Y, et al. Prognostic value and molecular landscape of HER2 low-expressing metastatic colorectal cancer. Clin Colorectal Cancer. 2021;20(2):113-120 e1. https://doi.org/10.1016/j.clcc.2020.11.002.

Article  PubMed  Google Scholar 

Siravegna G, Sartore-Bianchi A, Nagy RJ, et al. Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer. Clin Cancer Res. 2019;25(10):3046–53. https://doi.org/10.1158/1078-0432.CCR-18-3389.

CAS  Article  PubMed  Google Scholar 

Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17(6):738–46. https://doi.org/10.1016/S1470-2045(16)00150-9.

CAS  Article  PubMed  Google Scholar 

Ni S, Peng J, Huang D, et al. HER2 overexpression and amplification in patients with colorectal cancer (HOLIC): a large-scale retrospective study in Chinese population. Ann Oncol. 2017;28:v191. https://doi.org/10.1093/annonc/mdx393.089.

Article  Google Scholar 

Wu SW, Ma CC, Li WH. Does overexpression of HER-2 correlate with clinicopathological characteristics and prognosis in colorectal cancer? Evidence from a meta-analysis. Diagn Pathol. 2015;10:144. https://doi.org/10.1186/s13000-015-0380-3.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Richman SD, Southward K, Chambers P, et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol. 2016;238(4):562–70. https://doi.org/10.1002/path.4679.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Huang W, Chen Y, Chang W, et al. HER2 positivity as a biomarker for poor prognosis and unresponsiveness to anti-EGFR therapy in colorectal cancer. J Cancer Res Clin Oncol. 2021. https://doi.org/10.1007/s00432-021-03655-x.

Article  PubMed  PubMed Central  Google Scholar 

•• Siena S, Di Bartolomeo M, Raghav K, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2021;22(6):779–89. https://doi.org/10.1016/S1470-2045(21)00086-3. This is the most recent updated data presented at ASCO regarding the results of trastuzumab-deruxetan which was recently approved by the FDA in 2021 for the treatment of mCRC and was added to the 2021 guidelines.

CAS  Article  PubMed  Google Scholar 

Raghav K, Loree JM, Morris JS, et al. Validation of HER2 amplification as a predictive biomarker for anti–epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. JCO Precis Oncol. 2019;3:1–13. https://doi.org/10.1200/po.18.00226.

Article  PubMed  Google Scholar 

Nami B, Maadi H, Wang Z. Mechanisms underlying the action and synergism of trastuzumab and pertuzumab in targeting HER2-positive breast cancer. Cancers 2018;10(10):342. https://doi.org/10.3390/cancers10100342.

Tosi F, Sartore-Bianchi A, Lonardi S, et al. Long-term clinical outcome of trastuzumab and lapatinib for HER2-positive metastatic colorectal cancer. Clin Colorectal Cancer. 2020;19(4):256-262 e2. https://doi.org/10.1016/j.clcc.2020.06.009.

Article  PubMed  Google Scholar 

Sartore-Bianchi A, Lonardi S, Martino C, et al. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal